ARTICLE | Company News
University of Toronto, Advanced Proteome Therapeutics deal
October 24, 2016 7:00 AM UTC
The university’s Toronto Recombinant Antibody Centre (TRAC) granted Advanced Proteome an exclusive option to license preclinical oncology antibody candidates against an undisclosed target to develop antibody-drug conjugates (ADCs) using Advanced Proteome’s protein conjugation technology. The partners will conduct joint research to evaluate the ADCs. ...